The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux
Stopped early · Not applicable · Has a placebo group
Conditions studied: Laryngopharyngeal Reflux
In brief
Recent studies have demonstrated that patients with throat-related reflux often require twice daily proton pump inhibitor therapy to attain significant symptomatic improvement, with once daily therapy offering little relief. As dexlansoprazole is a twice-daily release proton pump inhibitor requiring only once-daily dosing, it may provide laryngopharyngeal reflux (LPR) symptomatic relief comparable to that of twice daily dosing, yet be more readily approved by third party payers because of its once daily dosing requirements. It is hypothesized that, in patients with pharyngeal-probe proven throat reflux, there will be significantly greater improvement in symptoms and pharyngeal probe findings in those patients receiving dexlansoprazole than those receiving placebo alone.
Key facts
- Study ID
- NCT01317472
- Run by
- Indiana University
- People needed
- 11
- Starts
- 2011-03-01
- Expected to finish
- 2013-11-01
- Last updated by the study team
- 2019-10-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Clarian North Hospital -- IUMG Clinic — Indianapolis, Indiana, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.